A Case of Rituximab-Induced Acute Thrombocytopenia in a Patient with Splenic Marginal Zone Lymphoma and Chronic Hepatitis C Virus Infection

Qureini, Aref; Asif, Samia; Harry, Stephanie; Madhusudhana, Sheshadri

doi:10.12659/ajcr.917644

Cited by 2 publications

(1 citation statement)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The patient was also using a nonsteroidal anti-inflammatory drug, and it was reported that RIAT developed after rituximab was administered for the first time. 5 This case made us think that comorbid diseases and drugs may play a role in the development of RIAT. Robinson et al reported a case of RIAT in a patient diagnosed with SMZL in 2020.…”

Section: Discussionmentioning

confidence: 99%

Rituximab-induced severe acute thrombocytopenia in a patient with splenic marginal zone lymphoma

Kars

Yorgancı

Yaşkıran

et al. 2022

J Oncol Pharm Pract

View full text Add to dashboard Cite

Introduction Rituximab, which is widely used in the treatment of B-cell lymphoma, is a chimeric monoclonal antibody directed against the CD20 antigen. Rituximab has many side effects, mainly allergic and neurological. Rituximab may cause thrombocytopenia in the long term after administration. Rare cases of rituximab-induced acute thrombocytopenia have been reported in the literature. Case Report A 51-year-old female patient who was newly diagnosed with splenic marginal zone lymphoma received rituximab as first-line therapy. Petechiae occurred in the lower extremities on the day following rituximab administration. The blood test showed a severe drop in the platelet count from 112,000/μL to 5000/μL. Blood peripheral smear evaluation confirmed severe thrombocytopenia. Management and outcome There was no change in hemoglobin or white blood cell levels. After the diagnosis of rituximab-induced acute thrombocytopenia, thrombocyte suspension was administered due to the risk of bleeding. Close clinical and laboratory observations were made. The platelet count began to rise gradually in the following period. Before the second week of rituximab administration, the platelet count was 122,000/μL. No complications developed after premedication and slow rituximab administration, and subsequent treatments were continued in the same way. Discussion Rituximab has widespread use, especially in malignancies and autoimmune diseases. Like many monoclonal antibodies, rituximab has several side effects. Thrombocytopenia is a long-term side effect associated with rituximab, and rituximab-induced severe acute thrombocytopenia has been rarely reported. Therefore, it should be kept in mind that severe acute thrombocytopenia may develop after rituximab administration.

show abstract

Section: Discussionmentioning

confidence: 99%